Toggle light / dark theme

Inching Towards the Regulatory Classification of Aging as a Disease

This post originally appeared at Fight Aging!

Sizable factions within the research and advocacy communities are very interested in having aging officially classified as a disease, meaning its inclusion in the International Classification of Diseases maintained by the World Health Organization, as that is the basis for the definition of disease used by national regulatory bodies. The view is that this would open the door to greater large-scale institutional funding, more relevant clinical trials for therapies targeting the mechanisms of aging, and that this greater level of funding and activity will percolate back down the chain of research and development to accelerate progress. I think this a reasonable argument to make, though I would advocate for greater effort to be placed on finding a way to bypass the system rather than change it directly – the threat of competition tends to be more effective than petitions as a way to force change.

Lobbyists have made more progress towards classifying aging as a disease. The World Health Organization (WHO) has implemented the extension code “Ageing-related” (XT9T) in the latest version of the International Classification of Diseases (ICD). The previous version, the ICD-10, was released in 1983 and is now replaced by the new version, the ICD-11, which is expected to serve the medical community for many years, much as its predecessor has.

Pomegranate compound with anti-aging effects passes human trial

Urolithin A, a metabolite of biomolecules found in pomegranates and other fruits, could help slow certain aging processes. EPFL spin-off Amazentis, in conjunction with EPFL and the Swiss Institute of Bioinformatics, has published a paper in the journal Nature Metabolism outlining the results of their clinical trial.

It is a fact of life that skeletal muscles begin to lose strength and mass once a person reaches the age of 50. A recent clinical trial involving two EPFL entities—spin-off Amazentis and the Laboratory of Integrative Systems Physiology (LISP) – showed that urolithin A, a compound derived from biomolecules found in fruits such as pomegranates, could slow down this process by improving the functioning of mitochondria—the cells’ powerhouses. A joint paper presenting the results of the trial, published today in Nature Metabolism, also demonstrates that ingesting the compound poses no risk to human health.

Anti-aging compound from pomegranates proves promising in human clinical trials

Since aging is a key driver of many diseases, targeting that process could be a handy catch-all for treating a range of diseases and improving quality of life for pretty much everybody. Researchers at EPFL have now reported a new step towards that goal, with human clinical trials of a fruit-derived compound showing promise in slowing mitochondrial aging in elderly patients, with no side effects found.

GSK partners with CRISPR pioneer Doudna to find new drugs

GSK forms CRISPR alliance with UC Berkeley and UCSF to create functional genomics insitute. The main one, technologywise, is this about using CRISPR as a gene function screen. One can do a gazillion experiments at once, fleshing out connections, sketching the biology, finding drug targets. http://bit.do/eU942


S AN FRANCISCO — The drug maker GlaxoSmithKline announced Thursday that it would team up with some of the nation’s most prominent CRISPR researchers to use the gene-editing technology in a search for new medicines, establishing a new lab in San Francisco and spending up to $67 million over five years.

Jennifer Doudna, the University of California, Berkeley, researcher who co-invented the CRISPR enzyme technology, will help lead the effort, along with Jonathan Weissman, a UC San Francisco researcher who has been using CRISPR to understand the function of individual human genes and how they work together. Both are Howard Hughes Medical Institute investigators.

The lab will be called the Laboratory for Genomic Research and will be based near UCSF’s Mission Bay campus. The money will fund 24 full-time University of California employees, in addition to as many as 14 full-time GSK employees. GSK’s machine learning and artificial intelligence groups will create computer systems that can handle the large amounts of data the project is expected to create. It will focus on immunology, oncology, and neurology.

Aubrey de Grey, PhD, Co-founder of SENS Research Foundation

Aubrey de Grey, Ph.D., Chief Science Officer and Co-founder of SENS Research Foundation, delivers an overview of aging and the many health problems that develop in our advanced years.

Dr. de Grey is a respected member of the science community; he is the noted biomedical gerontologist who devised the innovative SENS platform and co-founded the SENS Research Foundation to further it. Dr. de Grey has written about his work and as an established researcher, he has been appointed to the editorial and scientific advisory boards of many journals, organizations, etc. Dr. de Grey is a Fellow of the Gerontological Society of America as well as the American Aging Association. He holds a BA in Computer Science and a Ph.D. in Biology from the prestigious University of Cambridge.

Dr. de Grey discusses his research in aging and the motivations for tackling the career. As he states, aging is the number one medical problem as it causes more suffering. He was motivated to research in this area because he found that not enough was being done to focus on aging and the myriad of problems that come with it. He talks about the many excuses that are given as reasons to simply accept aging as it is, or not focus on it at all, such as “it’s inevitable…everything ages,” or the philosophical—“death gives meaning to life,” or social—“maybe we could do this, but it would create new problems worse than the problem we are solving.” And as the Ph.D. states, none of these excuses stand up to even the faintest scrutiny, however, they still remain quite popular.

Phosphorous and calcium in lobster will strengthen your bones

There are many nutritional and delicious benefits of eating lobster. Some of them include protecting heart health, increasing energy, decreasing inflammation, speeding healing, promoting growth, boosting brain functioning and building strong bones. Lobsters are shelled marine creatures which are taking parts of crustaceans. They have the scientific name Homarus nephrops. This scientific name is the North Atlantic variety. This undersea creature is having old look and it is considered to be luxury or delicacy food in many parts of the world. Nowadays lobster is exported to many parts of the world. They are particularly popular in North America. Lobsters are delicious food but they have high prices which is a reason why they are not consumed a lot. It is important to know that the lobster has high amounts of cholesterol and sodium. If you suffer from cardiovascular issues, high blood pressure or any other health condition, then you should not consume lobster because it has minerals and nutrients which are not ideal for these conditions. Every food should be consumed in moderation. Lobster is ideal food for people to get many vitamins and minerals that are essential for their health. People who live in North American coasts can have lobster in every time because here the price of it is very low.